Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a headband ease endometriosis pain? new study tests At-Home brain zaps

NCT ID NCT06974773

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a wearable device called NettleEndo, which delivers mild electrical stimulation to the brain, can reduce chronic pelvic pain in women with endometriosis. About 120 women will use the device at home for 20 minutes a day, five days a week, for 12 weeks. Half will receive real stimulation and half a sham (placebo) to see if the active device improves pain, mood, and sleep.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Female, 22-45 years old * Assigned female at birth * Fluent in English * Capacity to consent * Confirmed diagnosis of endometriosis by a qualified physician, via: * Laparoscopic surgery with biopsy-proven endometriosis, OR * Clear evidence of ovarian endometrioma or deep infiltrating endometriosis on ultrasound/MRI * Pain levels: For menstruating participants, all of the following need to be met: * Regular menstrual cycles (21-35 days) * Mean DYS NRS ≥4 during menstrual bleeding days (over the last 28 days, self-assessed) * AND Mean NMPP NRS ≥4 during non-menstrual days (over the last 28 days, self-assessed) For non-menstruating patients, all required: * Irregular/absent cycles OR post-hysterectomy OR surgically menopausal * Mean pelvic pain NRS ≥4 (over the last 28 days, self-assessed) * Pain present on ≥50% of days * Access to a smartphone with an internet data plan, phone must be iOS 13.4+, or Android 12+. * No hormonal contraception or at least 6 months of consistent adherence to any hormonal contraception (e.g., IUD, pill, injection). * Capacity to follow instructions and operate the study device. Exclusion Criteria * Pregnancy/breastfeeding or planning to become pregnant in next 6 months * History of epileptic neurological conditions in the immediate family * Severe/untreated neurological disease (e.g., epilepsy or seizure disorders, stroke or transient ischemic attack \[TIA\], subarachnoid hemorrhage, traumatic brain injury \[TBI\] with persistent neurological deficits, brain tumors \[malignant or benign\], multiple sclerosis, Parkinson's disease, Alzheimer's disease or other dementias, Huntington's disease, cerebral aneurysms or arteriovenous malformations \[AVMs\], active central nervous system infections \[e.g., meningitis, encephalitis\], hydrocephalus, other neurodegenerative diseases not otherwise specified, or any other neurological condition that, in the opinion of the principal investigator, may increase risk or interfere with study participation or outcomes) * Metal implants/electronic devices in brain, head, or neck area * Participating in any other clinical trial * History of stroke, brain surgery, tumors, head trauma * Active skin lesions, open wounds, cuts, or infections on the scalp * Active scalp conditions (dermatitis, eczema, psoriasis) * Significant scarring/burns/other skin damage on scalp * Schizophrenia or bipolar disorder * History of suicidal behavior or clinically significant self-injurious behavior (e.g., one or more suicide attempts, non-suicidal self-injury \[NSSI\], or other behaviors indicative of intent to harm oneself), as determined by participant self-report. * Treatment plan must be stabilized (≥6 weeks analgesic/ ≥6 months hormonal contraception, and crucially no new medication changes before randomization) * Planning to commence any new treatment during intervention period * Lack of capacity to consent * Participation in a neurotechnology or drug trial in the last 6 months. * Recent surgical intervention for endometriosis within 6 months of enrollment or planned surgical intervention for endometriosis during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dysmenorrhea endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alethios, Inc.

    RECRUITING

    San Francisco, California, 94109, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.